Ustekinumab use in patients with severe psoriasis co‐infected with hepatitis B and/or C

Abstract

Exacerbation or reactivation of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) in persons infected with psoriasis during treatment with biologics is a documented concern with use of tumor necrosis factor (TNF) inhibitors. Much less is known, however, about these risks in relation to newer biologic drugs including ustekinumab (interleukin (IL)‐12/23 inhibition).

This article is protected by copyright. All rights reserved.

https://ift.tt/2zp7UeM